Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Avivagen Inc VIVXF

Avivagen Inc. is a Canada-based life sciences company. The Company is focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting general health and performance. The Company’s operations as one segment, products based on OxC-beta Technology. It OxC-beta technology is derived from its discoveries about B-carotene and other carotenoids, compounds that give certain fruits and vegetables their bright colors. OxC- beta Livestock is a proprietary product, an alternative to the antibiotics commonly added to livestock feeds. The product is available for sale in the United States, Mexico, Philippines, Taiwan, New Zealand, Thailand, Australia and Malaysia. It offers OxC-beta to approximately 46.6 million food animals (poultry, swine, and dairy cattle), 133,820 dogs and 4,000 people.


GREY:VIVXF - Post by User

Bullboard Posts
Post by Bullboards_Sealon Apr 27, 2012 5:18pm
316 Views
Post# 19846185

NR - Chemaphor Announces Option Grants

NR - Chemaphor Announces Option Grants

Chemaphor Announces Option Grants

(via Thenewswire.ca)

OTTAWA, April 27, 2012 - Chemaphor Inc. (TSXV: CFR) today announced pursuant to the requirements of the TSX Venture Exchange, that it has granted options to purchase 96,000 common shares to outside members of its board of directors. The stock options were granted pursuant to the terms of Chemaphor's stock option plan and are exercisable at
.10 per share. These grants form part of a total annual remuneration package for board members. Stock option grants are subject to necessary regulatory approvals.

About Chemaphor

Chemaphor, a wellness company, is committed to developing and delivering products for animals and humans to assist in optimizing health and daily quality of life. Chemaphor is advancing product candidates for the food animal market, companion animal market and various potential human applications. More information can be found at www.chemaphor.com.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For more information:

David HankinsonGraham Burton, PhD

CEO, Chemaphor Inc.President and Co-Founder, Chemaphor Inc.

Phone: 902-825-9270Phone: 613-990-0969

d.hankinson@chemaphor.comg.burton@chemaphor.com

Bullboard Posts